Diagnosis and management of supraventricular tachycardias

Bibas, Lior; Levi, Michael; Essebag, Vidal

doi:10.1503/cmaj.160079

Cited by 26 publications

(22 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The zerofluoroscopy approach used the Ensite NavX system as the sole imaging modality for guiding procedures during the ablation of supraventricular tachyarrhythmia including AVNRT and AVRT. Our results demonstrated that the zero-fluoroscopy approach had equivalent safety, efficiency, and efficacy as the conventional approach, which utilized fluoroscopy with or without three dimensional mapping systems [13].…”

Section: Discussionmentioning

confidence: 73%

Zero-fluoroscopy approach for ablation of supraventricular tachycardia using the Ensite NavX system: a multicenter experience

Chen

Yan

Proietti

et al. 2020

BMC Cardiovasc Disord

View full text Add to dashboard Cite

Background: Three-dimensional electroanatomic mapping systems have demonstrated a significant reduction in radiation exposure during radiofrequency catheter ablation procedures. We aimed to investigate the safety, feasibility and efficacy of a completely zero-fluoroscopy approach for catheter ablation of supraventricular tachycardia using the Ensite NavX navigation system compared with a conventional fluoroscopy approach. Methods: A multicenter prospective non-randomized registry study was performed in seven centers from January 2013 to February 2018. Consecutive patients referred for catheter ablation of supraventricular tachycardia were assigned either to a completely zero-fluoroscopic approach (ZF) or conventional fluoroscopy approach (CF) according to the operator's preference. Patients with atrial tachycardia were excluded. Results: Totally, 1020 patients were enrolled in ZF group; 2040 patients ablated by CF approach were selected for controls. There was no significant difference between the zero-fluoroscopy group and conventional fluoroscopy group as to procedure time (60.3 ± 20.3 vs. 59.7 ± 22.6 min, P = 0.90), immediate success rate of procedure (98.8% vs. 99.2%, P = 0.22), arrhythmia recurrence (0.4% vs. 0.5%, P = 0.85), total success rate of procedure (98.4% vs. 98.8%, P = 0.39) or complications (1.1% vs. 1.5%, P = 0.41). Compared with the conventional fluoroscopy approach, the zerofluoroscopy approach provided similar outcomes without compromising the safety or efficacy of the procedure. Conclusion: The completely zero-fluoroscopy approach demonstrated safety and efficacy comparable to a conventional fluoroscopy approach for catheter ablation of supraventricular tachycardia, and mitigated radiation exposure to both patients and operators.

show abstract

Section: Discussionmentioning

confidence: 73%

Zero-fluoroscopy approach for ablation of supraventricular tachycardia using the Ensite NavX system: a multicenter experience

Chen

Yan

Proietti

et al. 2020

BMC Cardiovasc Disord

View full text Add to dashboard Cite

show abstract

“…However, second in incidence to AF is atrial flutter. Although occurring < 1/10 as often as AF, atrial flutter commonly coexists with or precedes AF and is 2½ times as common as paroxysmal supraventricular tachycardias [5, 6]. Typical atrial flutter is a macro-re-entrant tachycardia with an atrial rate of 300 bpm that almost always has an atrioventricular transmission of 2:1 resulting in a ventricular rate of 120–150 bpm [5].…”

Section: Discussionmentioning

confidence: 99%

Smart watch-detected tachycardia: a case of atrial flutter

Goldstein¹,

Wells

2019

Oxford Medical Case Reports

View full text Add to dashboard Cite

The use of smart watches like the Apple watch and other wearable electronic devices by the general public has been increasing dramatically. Until their accuracy for detecting dysrhythmias has been well-established, however, it would not be appropriate to rely on them solely to rule-in or rule-out pathology. Nonetheless, unusual findings from these devices should be followed up with more conventional investigations, and this approach may prove highly beneficial to patients and treating clinicians alike. This case demonstrates a diagnosis of atrial flutter that was suspected based on the Apple watch and iPhone Health app findings.

show abstract

“…С прогностической точки зрения эктопические тахиаритмии крайне неблагоприятны. Доказано, что постоянные ЭПТ в течение 11-12 мес приводят к развитию аритмогенной кардиомиопатии [24]. В частности, в исследовании H. Ge et al были изучены 115 детей с диагнозом «эктопическая предсердная тахикардия» [25].…”

Section: лечение и прогнозunclassified

“…Установлена четкая корреляция между эффективностью консервативной терапии и возрастом пациента. Наиболее адекватный ответ на антиаритмическую терапию наблюдается у детей до 1 года, при этом резистентность к терапии растет прямо пропорционально возрасту [24,25]. Была выведена наиболее оптимальная комбинация антиаритмических препаратов для купирования эктопических предсердных тахикардий, включающая применение соталола в дозировке 4,5-5,7 мг/кг/сут, разделенного на два приема с пропафеноном в дозировке 10-15 мг/кг/сут.…”

Section: лечение и прогнозunclassified

Disembriogenetic preconditions for the development of ectopic atrial tachycardias

Serguladze¹,

Tembotova²,

Suladze³

2019

AnnAritmol

View full text Add to dashboard Cite

show abstract

Diagnosis and management of supraventricular tachycardias

Abstract: • Patients with an asymptomatic accessory pathway should be referred for an exercise stress test, ambulatory ECG monitoring and possible electrophysiology study to assess their risk of arrhythmic events.

Cited by 26 publications

References 35 publications

Zero-fluoroscopy approach for ablation of supraventricular tachycardia using the Ensite NavX system: a multicenter experience

Zero-fluoroscopy approach for ablation of supraventricular tachycardia using the Ensite NavX system: a multicenter experience

Smart watch-detected tachycardia: a case of atrial flutter

Disembriogenetic preconditions for the development of ectopic atrial tachycardias

Contact Info

Product

Resources

About